Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema

PURPOSE: To compare blood pressure and urine albumin-creatinine ratio over time for participants receiving aflibercept, bevacizumab, or ranibizumab. METHODS: Preplanned secondary analyses from a randomized trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema (DME). Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Glassman, Adam R., Liu, Danni, Jampol, Lee M., Sun, Jennifer K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2018
Materias:
Physiology and Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837671/
https://www.ncbi.nlm.nih.gov/pubmed/29625440
http://dx.doi.org/10.1167/iovs.17-22853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837671/
https://www.ncbi.nlm.nih.gov/pubmed/29625440
http://dx.doi.org/10.1167/iovs.17-22853

Ejemplares similares